title: Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
abstract: OBJECTIVE
  Chemoresistance of breast cancer is a growing problem and still a major clinical obstacle to successful treatment in clinical patients. miR-760 was significantly downregulated in chemoresistance breast cancer tissues compared to chemo-sensitive tissues in our previous study. However, the role of miR-760 in modulating drug resistance remains largely unexplored. In this study, we sought to determine the expression pattern of miR-760 targeted mRNAs, and explore their potential functions and participated-pathways in breast cancer drug resistance cells.
  
  
  RESULTS
  Compared to parental cell line MCF-7, miR-760 was downregulated by 6.15 folds in MCF-7/Adr cells. The qRT-PCR result showed that compared to miR-760 negative control cells group, miR-760 was up-regulated 15.817 folds after miR-760 lentiviral transfection in miR-760 mimics group. The microarray data showed that 270 genes were dysregulated over 2-fold change in MCF-7/Adr cells after miR-760 overexpressed, including 241 up-regulated and 29 downregulated genes. GO analysis result appeared that the predicted target genes of miR-760 mainly regulated DNA binding, protein binding, molecular function, nucleic acid binding, and so on; the pathway analysis data demonstrated that these target genes mainly involved in cell cycle, TGF-beta signaling pathway, mRNA processing reactome, G protein signaling, apoptosis, Wnt signaling pathway, and other signaling pathways. There were 3 predicted target genes (RHOB, ANGOTL4, ABCA1) of miR-760 were selected at a P value<0.05 and the fold enrichment was>40.
  
  
  CONCLUSIONS
  Our study explored the genes expression pattern after miR-760 overexpresssed, and confirmed 3 dominantly dysregulated genes, which could expand the insights into the miR-760 function and molecular mechanisms in drug resistance of breast cancer. This study might afford a comprehensive understanding of miR-760 as prognostic biomarkers during clinical treatment, and we supposed that the miR-760 expression levels in drug resistance carcinoma tissues could be pursued to develop new strategies for targeted therapies in chemoresistant breast cancer patients.
authors: Yangzhou Maternal and Child Health Hospital, Affiliated with Yangzhou Medical University, Yangzhou 225002, China.
authors: Jianxin
authors: J
authors: Lv
authors: Nanjing Maternal and Child Health Medical Institute, Affiliated Nanjing Maternal and Child Health Hospital, Nanjing Medical University, Nanjing 210004, China.
authors: Ziyi
authors: Z
authors: Fu
authors: Yangzhou Maternal and Child Health Hospital, Affiliated with Yangzhou Medical University, Yangzhou 225002, China.
authors: Min
authors: M
authors: Shi
authors: The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin 214400, China.
authors: Kai
authors: K
authors: Xia
authors: Nanjing Maternal and Child Health Medical Institute, Affiliated Nanjing Maternal and Child Health Hospital, Nanjing Medical University, Nanjing 210004, China.
authors: Chenbo
authors: C
authors: Ji
authors: Nanjing Maternal and Child Health Medical Institute, Affiliated Nanjing Maternal and Child Health Hospital, Nanjing Medical University, Nanjing 210004, China.
authors: Pengfei
authors: P
authors: Xu
authors: Nanjing Maternal and Child Health Medical Institute, Affiliated Nanjing Maternal and Child Health Hospital, Nanjing Medical University, Nanjing 210004, China.
authors: Mingming
authors: M
authors: Lv
authors: Yangzhou Maternal and Child Health Hospital, Affiliated with Yangzhou Medical University, Yangzhou 225002, China.
authors: Bo
authors: B
authors: Pan
authors: Yangzhou Maternal and Child Health Hospital, Affiliated with Yangzhou Medical University, Yangzhou 225002, China.
authors: Luxian
authors: L
authors: Dai
authors: Nanjing Maternal and Child Health Medical Institute, Affiliated Nanjing Maternal and Child Health Hospital, Nanjing Medical University, Nanjing 210004, China; The People's Hospital of Jiangsu Province/The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. Electronic address: xhfybj@163.com.
authors: Hui
authors: H
authors: Xie
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D063990:Gene Ontology; D006801:Humans; D016086:Lentivirus / Q000378:metabolism; D061986:MCF-7 Cells; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000235:genetics; D014162:Transfection
chemical_list: C579293:MIRN760 microRNA, human; D035683:MicroRNAs; D004317:Doxorubicin
keywords: Breast cancer; Chemoresistance; Microarray; has-miR-760